cytochrome c oxidase assembly factor COX19Genealiases: []
Q-omics provides the consensus-scored COX19 profile across patient tissues and cancer cell-line models. COX19 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, COX19 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, COX19 RNA expression shows 19,257 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, HNSC, and ACC as cancer lineages where COX19 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for COX19 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes COX19 survival associations across molecular data types. COX19 RNA expression shows survival associations in the most cancer types (25), followed by mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible COX19 RNA expression–survival associations across cancer types. High COX19 expression shows unfavorable associations in KIRC, KICH, MESO, COAD, LIHC and LGG. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for COX19 RNA expression.
This table summarizes COX19 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for COX19. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. COX19 shows higher tumor expression in HNSC, KIRC, COAD, LIHC, STAD and BLCA. The HNSC box plot shows higher COX19 RNA expression in tumor versus normal tissue (log2 FC = +0.868, t-test p < 0.001).
This table shows molecular features associated with COX19 in patient tissues and cancer cell lines. In patient samples, COX19 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, COX19 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and UPPER_AERODIGESTIVE_TRACT.
